Boston Scientific (BSX) Ascends While Market Falls: Some Facts to Note

Boston Scientific (BSX) ended the recent trading session at $76.85, demonstrating a +1.45% change from the preceding day's closing price. This change outpaced the S&P 500's 0.43% loss on the day. Elsewhere, the Dow saw a downswing of 1.05%, while the tech-heavy Nasdaq depreciated by 0.92%.

Shares of the medical device manufacturer have depreciated by 17.96% over the course of the past month, underperforming the Medical sector's loss of 1.34%, and the S&P 500's loss of 0.5%.

The investment community will be closely monitoring the performance of Boston Scientific in its forthcoming earnings report. It is anticipated that the company will report an EPS of $0.79, marking a 5.33% rise compared to the same quarter of the previous year. Alongside, our most recent consensus estimate is anticipating revenue of $5.19 billion, indicating a 11.29% upward movement from the same quarter last year.

Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $3.46 per share and revenue of $22.32 billion, indicating changes of +13.07% and +11.16%, respectively, compared to the previous year.

Investors should also take note of any recent adjustments to analyst estimates for Boston Scientific. Such recent modifications usually signify the changing landscape of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.

Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.

The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. The Zacks Consensus EPS estimate has moved 0.36% higher within the past month. Boston Scientific is currently a Zacks Rank #3 (Hold).

With respect to valuation, Boston Scientific is currently being traded at a Forward P/E ratio of 21.91. This indicates a premium in contrast to its industry's Forward P/E of 20.66.

One should further note that BSX currently holds a PEG ratio of 1.05. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. Medical - Products stocks are, on average, holding a PEG ratio of 1.78 based on yesterday's closing prices.

The Medical - Products industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 139, placing it within the bottom 44% of over 250 industries.

The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.

Don't forget to use Zacks.com to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research